235 related articles for article (PubMed ID: 33045631)
1. Lack of protection against feline immunodeficiency virus infection among domestic cats in New Zealand vaccinated with the Fel-O-Vax® FIV vaccine.
Stickney A; Ghosh S; Cave NJ; Dunowska M
Vet Microbiol; 2020 Nov; 250():108865. PubMed ID: 33045631
[TBL] [Abstract][Full Text] [Related]
2. Dual-subtype vaccine (Fel-O-Vax FIV) protects cats against contact challenge with heterologous subtype B FIV infected cats.
Kusuhara H; Hohdatsu T; Okumura M; Sato K; Suzuki Y; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2005 Jul; 108(3-4):155-65. PubMed ID: 15899558
[TBL] [Abstract][Full Text] [Related]
3. Diagnosing feline immunodeficiency virus (FIV) and feline leukaemia virus (FeLV) infection: an update for clinicians.
Westman ME; Malik R; Norris JM
Aust Vet J; 2019 Mar; 97(3):47-55. PubMed ID: 30809813
[TBL] [Abstract][Full Text] [Related]
4. Feline immunodeficiency virus (FIV) infection in domestic pet cats in Australia and New Zealand: Guidelines for diagnosis, prevention and management.
Westman ME; Coggins SJ; van Dorsselaer M; Norris JM; Squires RA; Thompson M; Malik R
Aust Vet J; 2022 Aug; 100(8):345-359. PubMed ID: 35578381
[TBL] [Abstract][Full Text] [Related]
5. Duration of antibody response following vaccination against feline immunodeficiency virus.
Westman ME; Malik R; Hall E; Harris M; Hosie MJ; Norris JM
J Feline Med Surg; 2017 Oct; 19(10):1055-1064. PubMed ID: 27770018
[TBL] [Abstract][Full Text] [Related]
6. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Pu R; Coleman J; Coisman J; Sato E; Tanabe T; Arai M; Yamamoto JK
J Feline Med Surg; 2005 Feb; 7(1):65-70. PubMed ID: 15686976
[TBL] [Abstract][Full Text] [Related]
7. Antibody Responses in Cats Following Primary and Annual Vaccination against Feline Immunodeficiency Virus (FIV) with an Inactivated Whole-Virus Vaccine (Fel-O-Vax
Westman M; Yang D; Green J; Norris J; Malik R; Parr YA; McDonald M; Hosie MJ; VandeWoude S; Miller C
Viruses; 2021 Mar; 13(3):. PubMed ID: 33809232
[TBL] [Abstract][Full Text] [Related]
8. Neutralising antibody response in domestic cats immunised with a commercial feline immunodeficiency virus (FIV) vaccine.
Bęczkowski PM; Harris M; Techakriengkrai N; Beatty JA; Willett BJ; Hosie MJ
Vaccine; 2015 Feb; 33(8):977-84. PubMed ID: 25613718
[TBL] [Abstract][Full Text] [Related]
9. Serological differentiation of FIV-infected cats from dual-subtype feline immunodeficiency virus vaccine (Fel-O-Vax FIV) inoculated cats.
Kusuhara H; Hohdatsu T; Seta T; Nemoto K; Motokawa K; Gemma T; Watanabe R; Huang C; Arai S; Koyama H
Vet Microbiol; 2007 Mar; 120(3-4):217-25. PubMed ID: 17141431
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE
J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of a feline immunodeficiency virus vaccine.
Huang C; Conlee D; Loop J; Champ D; Gill M; Chu HJ
Anim Health Res Rev; 2004 Dec; 5(2):295-300. PubMed ID: 15984343
[TBL] [Abstract][Full Text] [Related]
12. Dual-subtype feline immunodeficiency virus vaccine provides 12 months of protective immunity against heterologous challenge.
Huang C; Conlee D; Gill M; Chu HJ
J Feline Med Surg; 2010 Jun; 12(6):451-7. PubMed ID: 20167521
[TBL] [Abstract][Full Text] [Related]
13. Differentiation of feline immunodeficiency virus vaccination, infection, or vaccination and infection in cats.
Levy JK; Crawford PC; Kusuhara H; Motokawa K; Gemma T; Watanabe R; Arai S; Bienzle D; Hohdatsu T
J Vet Intern Med; 2008; 22(2):330-4. PubMed ID: 18371028
[TBL] [Abstract][Full Text] [Related]
14. Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.
Sahay B; Yamamoto JK
Viruses; 2018 May; 10(5):. PubMed ID: 29789450
[TBL] [Abstract][Full Text] [Related]
15. The protective rate of the feline immunodeficiency virus vaccine: An Australian field study.
Westman ME; Malik R; Hall E; Harris M; Norris JM
Vaccine; 2016 Sep; 34(39):4752-4758. PubMed ID: 27522177
[TBL] [Abstract][Full Text] [Related]
16. Sequence variation of the feline immunodeficiency virus genome and its clinical relevance.
Stickney AL; Dunowska M; Cave NJ
Vet Rec; 2013 Jun; 172(23):607-14. PubMed ID: 23749359
[TBL] [Abstract][Full Text] [Related]
17. Feline immunodeficiency virus model for designing HIV/AIDS vaccines.
Yamamoto JK; Sanou MP; Abbott JR; Coleman JK
Curr HIV Res; 2010 Jan; 8(1):14-25. PubMed ID: 20210778
[TBL] [Abstract][Full Text] [Related]
18. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.
Hofmann-Lehmann R; Holznagel E; Aubert A; Ossent P; Reinacher M; Lutz H
Vet Immunol Immunopathol; 1995 May; 46(1-2):127-37. PubMed ID: 7618252
[TBL] [Abstract][Full Text] [Related]
19. Diagnosing feline immunodeficiency virus (FIV) infection in FIV-vaccinated and FIV-unvaccinated cats using saliva.
Westman ME; Malik R; Hall E; Norris JM
Comp Immunol Microbiol Infect Dis; 2016 Jun; 46():66-72. PubMed ID: 27260813
[TBL] [Abstract][Full Text] [Related]
20. Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins.
Leutenegger CM; Hofmann-Lehmann R; Holznagel E; Cuisinier AM; Wolfensberger C; Duquesne V; Cronier J; Allenspach K; Aubert A; Ossent P; Lutz H
AIDS Res Hum Retroviruses; 1998 Feb; 14(3):275-83. PubMed ID: 9491919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
